Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Claudia Ibarra departed as chief operating officer at DermTech, Inc..
- Action
- mutually agreed departure
- Role
- chief operating officer
Exact text from the filing
On January 29, 2024, Claudia Ibarra and the Company mutually agreed Ms. Ibarra’s last day of employment as chief operating officer of the Company will be February 2, 2024.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
DermTech, Inc. announced a restructuring with charges of approximately $1.3 million affecting operations (approximately 30 employees, or approximately 15% of the Company's workforce).
- Type
- restructuring
- Charge
- approximately $1.3 million
- Affected area
- operations
- Headcount
- approximately 30 employees, or approximately 15% of the Company's workforce
Exact text from the filing
On January 29, 2024, the Board of Directors (the “Board”) of DermTech, Inc. (the “Company”) approved a restructuring plan to continue to align the Company’s resources with its previously announced strategic prioritization for the DermTech Melanoma Test, further streamline operations and reduce overall operating expenses. The restructuring includes operating expense reductions and a reduction in force (the “Reduction in Force”). These additional restructuring actions will primarily affect operations, but impact the entire organization, and will result in a workforce reduction of approximately 30 employees, or approximately 15% of the Company's workforce. The Company expects to achieve approximately $40 million in total operating expense reductions compared to fiscal 2022, when combined with its initial restructuring plan announced in June 2023. The Company estimates that it will incur aggregate pre-tax charges of approximately $1.3 million in connection with the Reduction in Force, prim
View on SEC.gov